Lilly Brings Non-Inferiority Data To GLP-1 Show Down
This article was originally published in The Pink Sheet Daily
Executive Summary
In the competitive GLP-1 market, non-inferiority data against Novo Nordisk’s market-leading Victoza will go a long way toward strengthening the commercial case for Lilly’s once-weekly GLP-1, dulaglutide, pending at FDA.